News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
This unit will focus on the manufacturing of health and wellness equipment
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
Subscribe To Our Newsletter & Stay Updated
